Kasabach-Merritt syndrome: dangers of interferon and successful treatment with pentoxifylline.
A girl aged 3 months presented with thrombocytopenia and bruising around a large vascular malformation of her posterior abdominal wall. Treatment was started with corticosteroids and platelet replacement, but with no improvement and a platelet count persistently less than 10 x 10(9)/L over 3 weeks, alpha-interferon was added. There was an immediate increase in bruising, a fall in platelet count, and an increase in platelet transfusion requirement until interferon was discontinued 11 days later. After a further week, the platelet count returned to the levels before interferon, but the patient did not develop any further symptoms. The platelet count remained low with no clinical change until pentoxifylline was started at the age of 15 months. The platelet count rose to 117 x 10(9)/L within 4 days and remained more than 100 x 10(9)/L thereafter. The patient is now 7 years old and has had no recurrence since stopping the pentoxifylline at the age of 5 years. Although thrombocytopenia is a recognized side effect of interferon therapy, this very dangerous complication has not been previously reported using interferon for the Kasabach-Merritt syndrome.
de la Hunt
Michael N
MN
Department of Paediatric Surgery, Royal Victoria Infirmary, Newcastle-upon-Tyne, NE1 4LP, UK.
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D018324:Hemangioma, Capillary / Q000188:drug therapy*; D006401:Hematologic Agents / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D013577:Syndrome; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D006401:Hematologic Agents; D016898:Interferon-alpha; D010431:Pentoxifylline